Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OCGN with free AI briefings, catalyst countdowns, and dilution alerts.

OCGN · Ocugen, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$84.3M Cash on Hand
18.1mo Cash Runway
31.7% Short Interest
$12.17 Analyst Target (6)
Follow OCGN by email Get an email when OCGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OCGN, unsubscribe in one click. Privacy

📣 What OCGN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Whole-Virion Inactivated SARS-CoV-2 Vaccine… COVID-19 Phase 2/3 · NCT05258669 Unknown
OCU410 Dry Age-related Macular Degeneration Phase 3 · NCT07770828 Recruiting
OCU410ST Stargardt Disease Phase 2/3 · NCT05956626 Active not recruiting
Brimonidine Dry Eye Phase 2 · NCT03418727 Completed
Brimonidine Mono Therapy Dry Eye Phase 2 · NCT03418727 Completed
Corticosteroid-containing Eye Drop Dry Eye Phase 2 · NCT03418727 Completed
OCU400 Retinitis Pigmentosa Phase 1/2 · NCT05203939 Active not recruiting
OCU400 Med Dose Retinitis Pigmentosa Phase 1/2 · NCT05203939 Active not recruiting
OCU400 Second Eye Dosing Retinitis Pigmentosa Phase 1/2 · NCT05203939 Active not recruiting
sodium carboxymethylcellulose Dry Eye Phase 2 · NCT03418727 Completed
OCU200 Center Involved Diabetic Macular Edema Phase 1 · NCT05802329 Recruiting

Also used in these trials (approved or third-party drugs, not OCGN's own candidates): Brimonidine Tartrate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

OCGN holds $84.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $14M/quarter from operations, an estimated runway of 18.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 33 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OCGN files for a raise →

👥 Who Owns OCGN

Insiders 2.2% Other 5%+ holders 5% Institutions (193 holders) 41.3% Public and other holders 51.5%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 26,952,492 7.94% 2026-06-30
STATE STREET CORPORATION Institution (13G, 5%+) 21,469,307 6.33% 2026-06-30
Millennium Management LLC 5%+ holder (13G) 17,074,584 5.03% 2026-04-09
Vanguard Capital Management LLC Institution (13F) 14,140,436 4.17% 2026-09-30
UBS Group AG Institution (13F) 9,555,521 2.82% 2026-09-30
Geode Capital Management, LLC Institution (13F) 8,662,430 2.55% 2026-09-30
RTW Investments LP Institution (13F) 6,666,666 1.96% 2026-09-30
Shankar Musunuri
Chief Executive Officer, Director · +5.44M options
Insider 5,049,241 1.49% 2026-10-09
Two Sigma Investments, LP Institution (13F) 3,941,300 1.16% 2026-09-30
Ikarian Capital, LLC Institution (13F) 3,562,972 1.05% 2026-09-30
GMT Capital Corp Institution (13F) 3,505,398 1.03% 2026-09-30
Hennion & Walsh Asset Management, Inc. Institution (13F) 3,385,645 1.00% 2026-09-30

Share count 339,306,603 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-09
filed 2026-10-13
Musunuri Shankar
Sale (S) 468,727 $0.95 4,018,470
2026-10-09
filed 2026-10-13
Musunuri Shankar
Sale (S) 57,264 $0.95 1,030,771
2026-09-09
filed 2026-09-11
Musunuri Shankar
Sale (S) 468,727 $1.12 4,487,197
2026-09-09
filed 2026-09-11
Musunuri Shankar
Sale (S) 57,264 $1.12 1,088,035
2026-06-15
filed 2026-06-17
Johnson-Greene Treerita Essalima
Purchase (P) 21,000 $1.23 521,000

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full OCGN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OCGN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.